<DOC>
	<DOCNO>NCT00318513</DOCNO>
	<brief_summary>The purpose study determine safety side effect bevacizumab subject lymphedema initially receive bevacizumab alone combination standard manual lymphatic drainage ( MLD ) combine decongestive therapy ( CDT ) . This study help determine dose bevacizumab use future study subject lymphedema .</brief_summary>
	<brief_title>Safety Study Bevacizumab Treat Women With History Breast Cancer Suffering From Upper Extremity Lymphedema</brief_title>
	<detailed_description>Lymphedema occur vary frequency patient cancer approximately 10-15 % breast cancer patient develop lymphedema follow breast cancer treatment . Lymphedema breast cancer patient follow axillary lymph node dissection cause interruption axillary lymphatic system surgery radiation therapy , cause accumulation fluid subcutaneous tissue arm , decreased distensibility tissue around joint increase weight extremity . The primary current therapy employ involve complete decongestive therapy ( CDT ) encompass use manual lymphatic drainage ( MLD ) compression bandaging ( CB ) affect limb . The specific contribution vascular system development lymphedema unclear . Vascular permeability complex process primarily control interaction ligand vascular endothelial growth factor ( VEGF ) . As result understand biology VEGF anecdotal appreciation woman lymphedema note improvement lymphedema VEGF inhibitor therapy , hypothesize reduction vascular permeability result use VEGF inhibitor either alone conjunction standard decongestive lymphedema therapy may significantly improve outcome patient post-operative complication . Bevacizumab recombinant humanize monoclonal antibody direct VEGF . Bevacizumab block development new blood vessel cancer approve FDA treatment colon cancer combination chemotherapy . While bevacizumab administer thousand patient cancer , limited information use bevacizumab subject without active cancer . This study evaluate safety profile escalate dos bevacizumab administer intravenously alone 4 week follow 4 week therapy combination manual lymph drainage ( MLD ) compression bandaging ( CB ) patient moderate severe unilateral upper extremity lymphedema due prior breast cancer therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Women history breast cancer status post ( s/p ) prior surgical resection ( i.e. , either lumpectomy radiation , modify radical mastectomy radical mastectomy ) lymphedema define difference limb volume least 500 ml perometric assessment Lymphedema may newly diagnose previously treat long Stage I ( pit ) II ( fibrosis ) time study entry . No known evidence recurrent active metastatic breast cancer No prior chemotherapy within 6 month study entry recover grade 1 less toxicity prior chemotherapy radiation therapy ( exception alopecia ) ; ongoing antiestrogen therapy postmenopausal survivor permissible . Normal end organ function define : serum creatinine &lt; 1.5 mg/dl calculate creatinine clearance &gt; 50 ml/min ; SGOT SGPT &lt; 2.5 X upper limit normal ( ULN ) ; total bilirubin &lt; 1.5 X ULN ; absolute neutrophil count ( ANC ) &gt; 1,500 cells/µl ; hemoglobin &gt; 10 g/dl ( without transfusion ) ; platelet count &gt; 100,000/µl ; serum albumin within normal limit ( WNL ) . Stage III ( lymphostatic elephantiasis ) lymphedema Clinical evidence bilateral lymphedema . Those patient undergone bilateral breast cancer surgery prophylactic mastectomy noncancerous breast exclude . Any prior history deep venous thrombosis ( DVT ) pulmonary embolus ( exception prior linerelated thrombotic event ) myocardial infarction ( MI ) , cerebrovascular accident ( CVA ) arterial thromboembolic event ( i.e. , transient ischemic attack [ TIA ] , reversible ischemic neurologic deficit [ RIND ] , history angina pectoris , clinically significant peripheral vascular disease claudication , etc . ) Patients problem wound heal ( e.g. , diabetic ulcer ) , gastrointestinal fistula Patients receive therapeutic anticoagulation include full dose aspirin nonsteroidal antiinflammatory agent know inhibit platelet function ( low dose coumadin port prophylaxis low dose aspirin allow ) Untreated hypertension baseline systolic blood pressure ( SBP ) &gt; 150 mmHg diastolic blood pressure ( DBP ) &gt; 100 mmHg exclude ( stable treat hypertension value less noted eligible ) . A history infectious complication involve arm contraindication MLD + CB [ e.g. , congestive heart failure ( CHF ) , DVT , acute chronic renal failure ] exclude . Women history CHF [ New York Heart Association ( NYHA ) Class II great ] exclude . Pregnant breastfeed Unwilling use appropriate form barrier contraception duration study three month follow last dose bevacizumab Those patient actively undergo MLD and/or CB time study entry 4 week prior entry Unable provide write informed consent comply study procedure Baseline urine protein : creatinine ratio &gt; 1.0 Known evidence bleed diathesis coagulopathy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>lymphedema</keyword>
	<keyword>extremity</keyword>
	<keyword>woman</keyword>
</DOC>